ArticleMolecular and clinical oncology2025
Drug-induced interstitial lung disease caused by gefitinib in the treatment of non-small cell lung cancer: A case report.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gefitinib, a first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is widely used in treating non-small cell lung cancer (NSCLC) with EGFR mutations. Although effective, gefitinib is associated with rare but life-threatening interstitial lung disease (ILD). In the present study, a 68-year-old male with stage IIIB lung adenocarcinoma was reported, who developed acute interstitial pneumonia 20 days after initiating gefitinib therapy. The patient presented with high fever (41˚C), dyspnea and hypoxemia. Chest CT revealed bilateral diffuse interstitial infiltrates and pleural effusion. After excluding infectious and cardiac etiologies, gefitinib-induced ILD was diagnosed. Immediate discontinuation of gefitinib, combined with high-dose glucocorticoids (methylprednisolone 80 mg/day) and oxygen therapy, led to clinical improvement. However, ILD recurred upon rechallenge with the original gefitinib dose. This case highlights the importance of early recognition and prompt management of EGFR-TKI-related ILD. The challenges of rechallenging EGFR-TKIs post-recovery was further discussed and the need for personalized risk-benefit assessments was emphasized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.